Click here to get full coverage on New cancer drugs show tumor shrinkage in early trials - Stock Titan

New cancer drugs show tumor shrinkage in early trials  Stock Titan

New cancer drugs show tumor shrinkage in early trials - Stock Titan

Click here to get full coverage on Acrivon Therapeutics Stock (ACRV) Sinks despite Positive Cancer Trial Results - TipRanks

Acrivon Therapeutics Stock (ACRV) Sinks despite Positive Cancer Trial Results  TipRanks

Acrivon Therapeutics Stock (ACRV) Sinks despite Positive Cancer Trial Results - TipRanks

Click here to get full coverage on U.S. Initial Jobless Claims Rise to 208,000, Mixed Market Reaction - Intellectia AI

U.S. Initial Jobless Claims Rise to 208,000, Mixed Market Reaction  Intellectia AI

U.S. Initial Jobless Claims Rise to 208,000, Mixed Market Reaction - Intellectia AI

Click here to get full coverage on Acrivon Therapeutics Stock (ACRV) Opinions on Clinical Data Release - Quiver Quantitative

Acrivon Therapeutics Stock (ACRV) Opinions on Clinical Data Release  Quiver Quantitative

Acrivon Therapeutics Stock (ACRV) Opinions on Clinical Data Release - Quiver Quantitative

Click here to get full coverage on Piper Sandler Maintains Acrivon Therapeutics(ACRV.US) With Buy Rating, Raises Target Price to $8 - 富途牛牛

Piper Sandler Maintains Acrivon Therapeutics(ACRV.US) With Buy Rating, Raises Target Price to $8  富途牛牛

Piper Sandler Maintains Acrivon Therapeutics(ACRV.US) With Buy Rating, Raises Target Price to $8 - 富途牛牛

Click here to get full coverage on Acrivon Therapeutics (NASDAQ:ACRV) Stock Rating Lowered by Wall Street Zen - MarketBeat

Acrivon Therapeutics (NASDAQ:ACRV) Stock Rating Lowered by Wall Street Zen  MarketBeat

Acrivon Therapeutics (NASDAQ:ACRV) Stock Rating Lowered by Wall Street Zen - MarketBeat

Click here to get full coverage on Acrivon Therapeutics stock plunges after mixed cancer trial results - Investing.com

Acrivon Therapeutics stock plunges after mixed cancer trial results  Investing.com

Acrivon Therapeutics stock plunges after mixed cancer trial results - Investing.com

Click here to get full coverage on After-Hours Gainers: ALXO, GMED, ACRV, And Biotech Peers Rally On Trial Data And Earnings Updates - Nasdaq

After-Hours Gainers: ALXO, GMED, ACRV, And Biotech Peers Rally On Trial Data And Earnings Updates  Nasdaq

After-Hours Gainers: ALXO, GMED, ACRV, And Biotech Peers Rally On Trial Data And Earnings Updates - Nasdaq

Click here to get full coverage on H.C. Wainwright Initiates Coverage on Acrivon Therapeutics (ACRV) With “Buy” Rating and $19 PT - Yahoo Finance

H.C. Wainwright Initiates Coverage on Acrivon Therapeutics (ACRV) With “Buy” Rating and $19 PT  Yahoo Finance

H.C. Wainwright Initiates Coverage on Acrivon Therapeutics (ACRV) With “Buy” Rating and $19 PT - Yahoo Finance

Click here to get full coverage on Acrivon Therapeutics Announces Positive ACR-368 Phase 2b - GlobeNewswire

Acrivon Therapeutics Announces Positive ACR-368 Phase 2b  GlobeNewswire

Acrivon Therapeutics Announces Positive ACR-368 Phase 2b - GlobeNewswire

Click here to get full coverage on Acrivon Therapeutics Inc. (ACRV) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade

Acrivon Therapeutics Inc. (ACRV) Stock Price | Live Quotes & Charts | NASDAQ  StocksToTrade

Acrivon Therapeutics Inc. (ACRV) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade

Click here to get full coverage on 1/8/2026 Market Update - Winners: FLYX, PAPL, ELVN - Losers: ELME, IMRX, ACRV - S&P 500: 0.01% - Trefis

1/8/2026 Market Update - Winners: FLYX, PAPL, ELVN - Losers: ELME, IMRX, ACRV - S&P 500: 0.01%  Trefis

1/8/2026 Market Update - Winners: FLYX, PAPL, ELVN - Losers: ELME, IMRX, ACRV - S&P 500: 0.01% - Trefis

Click here to get full coverage on Why Is Acrivon Therapeutics Stock Falling Today? - Acrivon Therapeutics (NASDAQ:ACRV) - Benzinga

Why Is Acrivon Therapeutics Stock Falling Today? - Acrivon Therapeutics (NASDAQ:ACRV)  Benzinga

Why Is Acrivon Therapeutics Stock Falling Today? - Acrivon Therapeutics (NASDAQ:ACRV) - Benzinga

Click here to get full coverage on New data on experimental cancer drugs ACR-368 and ACR-2316 coming - Stock Titan

New data on experimental cancer drugs ACR-368 and ACR-2316 coming  Stock Titan

New data on experimental cancer drugs ACR-368 and ACR-2316 coming - Stock Titan

Click here to get full coverage on HC Wainwright & Co. Reiterates Acrivon Therapeutics (ACRV) Buy Recommendation - Nasdaq

HC Wainwright & Co. Reiterates Acrivon Therapeutics (ACRV) Buy Recommendation  Nasdaq

HC Wainwright & Co. Reiterates Acrivon Therapeutics (ACRV) Buy Recommendation - Nasdaq

Click here to get full coverage on Here's Why We're Watching Acrivon Therapeutics' (NASDAQ:ACRV) Cash Burn Situation - Yahoo Finance

Here's Why We're Watching Acrivon Therapeutics' (NASDAQ:ACRV) Cash Burn Situation  Yahoo Finance

Here's Why We're Watching Acrivon Therapeutics' (NASDAQ:ACRV) Cash Burn Situation - Yahoo Finance

Click here to get full coverage on New Analyst Forecast: $ACRV Given $8.0 Price Target | ACRV Stock News - Quiver Quantitative

New Analyst Forecast: $ACRV Given $8.0 Price Target | ACRV Stock News  Quiver Quantitative

New Analyst Forecast: $ACRV Given $8.0 Price Target | ACRV Stock News - Quiver Quantitative

Click here to get full coverage on Acrivon Therapeutics (NASDAQ: ACRV) advances ACR-368 Phase 2b; cash $134.4M - Stock Titan

Acrivon Therapeutics (NASDAQ: ACRV) advances ACR-368 Phase 2b; cash $134.4M  Stock Titan

Acrivon Therapeutics (NASDAQ: ACRV) advances ACR-368 Phase 2b; cash $134.4M - Stock Titan

Click here to get full coverage on Here's Why Acrivon Therapeutics, Inc. (ACRV) Is a Great 'Buy the Bottom' Stock Now - Yahoo Finance

Here's Why Acrivon Therapeutics, Inc. (ACRV) Is a Great 'Buy the Bottom' Stock Now  Yahoo Finance

Here's Why Acrivon Therapeutics, Inc. (ACRV) Is a Great 'Buy the Bottom' Stock Now - Yahoo Finance

Click here to get full coverage on Will Acrivon Therapeutics (NASDAQ:ACRV) Spend Its Cash Wisely? - simplywall.st

Will Acrivon Therapeutics (NASDAQ:ACRV) Spend Its Cash Wisely?  simplywall.st

Will Acrivon Therapeutics (NASDAQ:ACRV) Spend Its Cash Wisely? - simplywall.st

Click here to get full coverage on 225,000 Stock Options: Biotech Acrivon Therapeutics Awards Major Inducement Grant to Key New Hire - Stock Titan

225,000 Stock Options: Biotech Acrivon Therapeutics Awards Major Inducement Grant to Key New Hire  Stock Titan

225,000 Stock Options: Biotech Acrivon Therapeutics Awards Major Inducement Grant to Key New Hire - Stock Titan

Click here to get full coverage on Focused Clinical Strategy and Accelerated Approval Path for ACR-368 in High-Need Serous Endometrial Cancer Underpin ACRV Buy Rating - TipRanks

Focused Clinical Strategy and Accelerated Approval Path for ACR-368 in High-Need Serous Endometrial Cancer Underpin ACRV Buy Rating  TipRanks

Focused Clinical Strategy and Accelerated Approval Path for ACR-368 in High-Need Serous Endometrial Cancer Underpin ACRV Buy Rating - TipRanks

Click here to get full coverage on Acrivon (NASDAQ: ACRV) unveils AP3 KaiSR and ACR-2316 data in 3 AACR-NCI-EORTC posters - Stock Titan

Acrivon (NASDAQ: ACRV) unveils AP3 KaiSR and ACR-2316 data in 3 AACR-NCI-EORTC posters  Stock Titan

Acrivon (NASDAQ: ACRV) unveils AP3 KaiSR and ACR-2316 data in 3 AACR-NCI-EORTC posters - Stock Titan

Click here to get full coverage on 3 Promising Penny Stocks With Market Caps Over $70M - simplywall.st

3 Promising Penny Stocks With Market Caps Over $70M  simplywall.st

3 Promising Penny Stocks With Market Caps Over $70M - simplywall.st

Click here to get full coverage on Acrivon Therapeutics to Provide Clinical Data and Updates on ACR-368 and ACR-2316 in January 2026 - Quiver Quantitative

Acrivon Therapeutics to Provide Clinical Data and Updates on ACR-368 and ACR-2316 in January 2026  Quiver Quantitative

Acrivon Therapeutics to Provide Clinical Data and Updates on ACR-368 and ACR-2316 in January 2026 - Quiver Quantitative

Click here to get full coverage on Acrivon Therapeutics Inc.: Rise or Retreat? - StocksToTrade

Acrivon Therapeutics Inc.: Rise or Retreat?  StocksToTrade

Acrivon Therapeutics Inc.: Rise or Retreat? - StocksToTrade

Click here to get full coverage on ACRV: HC Wainwright Reiterates 'Buy' Rating and $19 Price Target | ACRV Stock News - GuruFocus

ACRV: HC Wainwright Reiterates 'Buy' Rating and $19 Price Target | ACRV Stock News  GuruFocus

ACRV: HC Wainwright Reiterates 'Buy' Rating and $19 Price Target | ACRV Stock News - GuruFocus

Click here to get full coverage on Tech Rally: Is ACRV stock a buy before product launches - Market Risk Analysis & Real-Time Volume Analysis Alerts - moha.gov.vn

Tech Rally: Is ACRV stock a buy before product launches - Market Risk Analysis & Real-Time Volume Analysis Alerts  moha.gov.vn

Tech Rally: Is ACRV stock a buy before product launches - Market Risk Analysis & Real-Time Volume Analysis Alerts - moha.gov.vn

Click here to get full coverage on Analysts Predict Up to 550% Rally for These 2 ‘Strong Buy’ Penny Stocks - Yahoo Finance

Analysts Predict Up to 550% Rally for These 2 ‘Strong Buy’ Penny Stocks  Yahoo Finance

Analysts Predict Up to 550% Rally for These 2 ‘Strong Buy’ Penny Stocks - Yahoo Finance

Click here to get full coverage on Here's Why Acrivon Therapeutics, Inc. (ACRV) is Poised for a Turnaround After Losing -52.81% in 4 Weeks - Yahoo Finance

Here's Why Acrivon Therapeutics, Inc. (ACRV) is Poised for a Turnaround After Losing -52.81% in 4 Weeks  Yahoo Finance

Here's Why Acrivon Therapeutics, Inc. (ACRV) is Poised for a Turnaround After Losing -52.81% in 4 Weeks - Yahoo Finance

Click here to get full coverage on Down -70.22% in 4 Weeks, Here's Why You Should You Buy the Dip in Acrivon Therapeutics, Inc. (ACRV) - Yahoo Finance

Down -70.22% in 4 Weeks, Here's Why You Should You Buy the Dip in Acrivon Therapeutics, Inc. (ACRV)  Yahoo Finance

Down -70.22% in 4 Weeks, Here's Why You Should You Buy the Dip in Acrivon Therapeutics, Inc. (ACRV) - Yahoo Finance

Click here to get full coverage on Is Acrivon Stock Climbing Too High? - timothysykes.com

Is Acrivon Stock Climbing Too High?  timothysykes.com

Is Acrivon Stock Climbing Too High? - timothysykes.com

Click here to get full coverage on 12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session  Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga

Click here to get full coverage on 12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session  Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga

Click here to get full coverage on Acrivon Highlights Promising ACR-368 Phase 2b Endometrial Data - TipRanks

Acrivon Highlights Promising ACR-368 Phase 2b Endometrial Data  TipRanks

Acrivon Highlights Promising ACR-368 Phase 2b Endometrial Data - TipRanks

Click here to get full coverage on Acrivon Showcases Promising Phase 2b Oncology Data Update - TipRanks

Acrivon Showcases Promising Phase 2b Oncology Data Update  TipRanks

Acrivon Showcases Promising Phase 2b Oncology Data Update - TipRanks

Click here to get full coverage on How ACRV stock compares to market leaders - Bull Run & High Yield Equity Trading Tips - Улправда

How ACRV stock compares to market leaders - Bull Run & High Yield Equity Trading Tips  Улправда

How ACRV stock compares to market leaders - Bull Run & High Yield Equity Trading Tips - Улправда

Click here to get full coverage on Why AZZ Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket - Benzinga

Why AZZ Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket  Benzinga

Why AZZ Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket - Benzinga

Click here to get full coverage on Spotlight On 3 Promising Penny Stocks With Over $50M Market Cap - simplywall.st

Spotlight On 3 Promising Penny Stocks With Over $50M Market Cap  simplywall.st

Spotlight On 3 Promising Penny Stocks With Over $50M Market Cap - simplywall.st

Click here to get full coverage on Dow Jumps Over 250 Points; US Initial Jobless Claims Increase - Benzinga

Dow Jumps Over 250 Points; US Initial Jobless Claims Increase  Benzinga

Dow Jumps Over 250 Points; US Initial Jobless Claims Increase - Benzinga

Click here to get full coverage on Volume Report: Is ACRV stock ready for breakout - 2025 Support & Resistance & AI Powered Buy/Sell Recommendations - Улправда

Volume Report: Is ACRV stock ready for breakout - 2025 Support & Resistance & AI Powered Buy/Sell Recommendations  Улправда

Volume Report: Is ACRV stock ready for breakout - 2025 Support & Resistance & AI Powered Buy/Sell Recommendations - Улправда

Click here to get full coverage on Nasdaq Falls Over 100 Points; Acuity Posts Upbeat Earnings - Benzinga

Nasdaq Falls Over 100 Points; Acuity Posts Upbeat Earnings  Benzinga

Nasdaq Falls Over 100 Points; Acuity Posts Upbeat Earnings - Benzinga

Click here to get full coverage on Acrivon Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights - Yahoo Finance

Acrivon Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights  Yahoo Finance

Acrivon Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights - Yahoo Finance

Click here to get full coverage on 12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session  Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga

Click here to get full coverage on Can ACRV stock sustain institutional interest - July 2025 Sector Moves & Smart Allocation Stock Reports - Улправда

Can ACRV stock sustain institutional interest - July 2025 Sector Moves & Smart Allocation Stock Reports  Улправда

Can ACRV stock sustain institutional interest - July 2025 Sector Moves & Smart Allocation Stock Reports - Улправда

Click here to get full coverage on Acrivon Therapeutics downgraded to Hold from Buy at JonesResearch - Yahoo Finance

Acrivon Therapeutics downgraded to Hold from Buy at JonesResearch  Yahoo Finance

Acrivon Therapeutics downgraded to Hold from Buy at JonesResearch - Yahoo Finance

Click here to get full coverage on Acrivon Therapeutics Highlights Synergy in Updated Presentation - TipRanks

Acrivon Therapeutics Highlights Synergy in Updated Presentation  TipRanks

Acrivon Therapeutics Highlights Synergy in Updated Presentation - TipRanks

Click here to get full coverage on Small-Cap Acrivon Showcases Tumor Reduction and Clinical Advancement in Major Trials, Shares Decline - Bitget

Small-Cap Acrivon Showcases Tumor Reduction and Clinical Advancement in Major Trials, Shares Decline  Bitget

Small-Cap Acrivon Showcases Tumor Reduction and Clinical Advancement in Major Trials, Shares Decline - Bitget

Click here to get full coverage on Citizens analyst reiterates Market Outperform rating on Acrivon stock - Investing.com

Citizens analyst reiterates Market Outperform rating on Acrivon stock  Investing.com

Citizens analyst reiterates Market Outperform rating on Acrivon stock - Investing.com

Click here to get full coverage on How ACRV stock compares to market leaders - Bond Market & Weekly Momentum Picks - Улправда

How ACRV stock compares to market leaders - Bond Market & Weekly Momentum Picks  Улправда

How ACRV stock compares to market leaders - Bond Market & Weekly Momentum Picks - Улправда

Click here to get full coverage on Is ACRV stock a buy before product launches - 2025 Price Momentum & Free Community Consensus Stock Picks - Улправда

Is ACRV stock a buy before product launches - 2025 Price Momentum & Free Community Consensus Stock Picks  Улправда

Is ACRV stock a buy before product launches - 2025 Price Momentum & Free Community Consensus Stock Picks - Улправда

Click here to get full coverage on Is ACRV stock ready for breakout - 2025 Support & Resistance & AI Powered Buy/Sell Recommendations - Улправда

Is ACRV stock ready for breakout - 2025 Support & Resistance & AI Powered Buy/Sell Recommendations  Улправда

Is ACRV stock ready for breakout - 2025 Support & Resistance & AI Powered Buy/Sell Recommendations - Улправда

Click here to get full coverage on Is ACRV stock a buy before product launches - Trade Signal Summary & Weekly Top Performers Watchlists - Улправда

Is ACRV stock a buy before product launches - Trade Signal Summary & Weekly Top Performers Watchlists  Улправда

Is ACRV stock a buy before product launches - Trade Signal Summary & Weekly Top Performers Watchlists - Улправда

Click here to get full coverage on 12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session  Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga

Click here to get full coverage on Acrivon Therapeutics Inc. Shares Surge: Time to Invest? - StocksToTrade

Acrivon Therapeutics Inc. Shares Surge: Time to Invest?  StocksToTrade

Acrivon Therapeutics Inc. Shares Surge: Time to Invest? - StocksToTrade

Click here to get full coverage on Acrivon Therapeutics’ SWOT analysis: precision oncology stock at crossroads - Investing.com

Acrivon Therapeutics’ SWOT analysis: precision oncology stock at crossroads  Investing.com

Acrivon Therapeutics’ SWOT analysis: precision oncology stock at crossroads - Investing.com

Click here to get full coverage on Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast - The Manila Times

Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast  The Manila Times

Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast - The Manila Times

Click here to get full coverage on ACRV Stock Price and Chart — NASDAQ:ACRV - TradingView — Track All Markets

ACRV Stock Price and Chart — NASDAQ:ACRV  TradingView — Track All Markets

ACRV Stock Price and Chart — NASDAQ:ACRV - TradingView — Track All Markets

Click here to get full coverage on Can ACRV stock beat analyst upgrades - Bear Alert & Accurate Entry/Exit Alerts - Улправда

Can ACRV stock beat analyst upgrades - Bear Alert & Accurate Entry/Exit Alerts  Улправда

Can ACRV stock beat analyst upgrades - Bear Alert & Accurate Entry/Exit Alerts - Улправда

Click here to get full coverage on Here's Why You Should Buy Acrivon Therapeutics (ACRV) Stock - Zacks Investment Research

Here's Why You Should Buy Acrivon Therapeutics (ACRV) Stock  Zacks Investment Research

Here's Why You Should Buy Acrivon Therapeutics (ACRV) Stock - Zacks Investment Research

Click here to get full coverage on Acrivon Therapeutics, Inc. (ACRV) - Zacks Investment Research

Acrivon Therapeutics, Inc. (ACRV)  Zacks Investment Research

Acrivon Therapeutics, Inc. (ACRV) - Zacks Investment Research

Click here to get full coverage on Acrivon Therapeutics (ACRV) Stock Price, News & Analysis - MarketBeat

Acrivon Therapeutics (ACRV) Stock Price, News & Analysis  MarketBeat

Acrivon Therapeutics (ACRV) Stock Price, News & Analysis - MarketBeat

Click here to get full coverage on ACRV - Acrivon Therapeutics, Inc. Latest Stock News & Market Updates - Stock Titan

ACRV - Acrivon Therapeutics, Inc. Latest Stock News & Market Updates  Stock Titan

ACRV - Acrivon Therapeutics, Inc. Latest Stock News & Market Updates - Stock Titan

Click here to get full coverage on Breaking Down Acrivon: Deep Dive Into Revenue, Profitability, And Prospects (NASDAQ:ACRV) - Seeking Alpha

Breaking Down Acrivon: Deep Dive Into Revenue, Profitability, And Prospects (NASDAQ:ACRV)  Seeking Alpha

Breaking Down Acrivon: Deep Dive Into Revenue, Profitability, And Prospects (NASDAQ:ACRV) - Seeking Alpha

Click here to get full coverage on ACRV News Today | Why did Acrivon Therapeutics stock go up today? - MarketBeat

ACRV News Today | Why did Acrivon Therapeutics stock go up today?  MarketBeat

ACRV News Today | Why did Acrivon Therapeutics stock go up today? - MarketBeat

Click here to get full coverage on Perceptive Advisors buys $20 million in Acrivon Therapeutics stock - Investing.com

Perceptive Advisors buys $20 million in Acrivon Therapeutics stock  Investing.com

Perceptive Advisors buys $20 million in Acrivon Therapeutics stock - Investing.com

Click here to get full coverage on 2 Breakout Growth Stocks to Buy for the Long Haul - The Motley Fool

2 Breakout Growth Stocks to Buy for the Long Haul  The Motley Fool

ACRV

Price Chart

Key Statistics

Technicals

About ACRV

Latest News

New cancer drugs show tumor shrinkage in early trials - Stock Titan

Acrivon Therapeutics Stock (ACRV) Sinks despite Positive Cancer Trial Results - TipRanks

U.S. Initial Jobless Claims Rise to 208,000, Mixed Market Reaction - Intellectia AI

Advanced Charts

Top Gainers

Top Losers